Abstract
Introduction

41
After nearly three decades of clinical use, teicoplanin has maintained an important niche in the 42 antibiotic arsenal for the treatment of Gram-positive infections in patients with haematological 43 malignancy owing both to its activity against meticillin-resistant staphylococci and to its good safety 44 profile.
1 However, the increasing prevalence of teicoplanin-resistant organisms is posing new 45 challenges. [2] [3] [4] To conserve the integrity of this valuable antibiotic, it is imperative that it is used 46 wisely. 47
Inadequate antibiotic exposure in patients with haematological malignancy may result in a 48 considerable increase in infection-related morbidity and mortality.
5 Sub-therapeutic concentrations 49
are also regarded as a risk factor for the development of microbiological resistance to 50 glycopeptides. 6 Furthermore, the frequent antibiotic courses prescribed for these patients due to 51 infections that commonly occur in the presence of profound immunosuppression, predisposes these 52 patients to infection from less susceptible microorganisms.
7 Therefore, optimal teicoplanin doses at 53 the commencement of therapy should be considered an important goal to ensure rapid achievement 54 of therapeutic concentrations. 8 However, this goal can be confounded by use of dosing regimens 55 that do not account for the pathophysiological changes encountered in patients with haematological 56 malignancy. 8, 9 57 As teicoplanin is a hydrophilic, renally cleared and highly protein bound antibiotic, it is considered to 58 be at high risk of pharmacokinetic (PK) variability in the presence of various pathophysiological 59 conditions, many of which occur commonly in patients with haematological malignancy. 8, 10 Sepsis, 60 fluid overload, effusions, hypoalbuminaemia and altered renal function are common conditions in 61 these patients and, since these situations may often coexist in the same patient, drug dosing 62 requirements can be difficult to predict. 9, 10 This represents a significant challenge to clinicians given 63 stored at -80°C. Urine creatinine concentration was determined locally using an enzymatic method 116 performed on a Roche/Hitachi Cobas C702 AutoAnalyzer system (Roche Diagnostics GmbH, Mannheim, 117 Germany). Urine volume, serum creatinine concentration on the day of the urine collection and urine 118 creatinine concentration were used to calculate the measured CL CR . 119
MIC testing 120
The identification of isolates from study patients was determined locally by broth microdilution using a 121 VITEK®2 system (bioMérieux UK Ltd., Basingstoke, UK) as per routine care. 
Probability of target attainment (PTA) 151
Monte Carlo simulations (n=1000) were performed using the final covariate model in Pmetrics to 152 determine the PTA for various dosing regimens. A dosing regimen was considered acceptable if the 153 PTA was ≥90%. IV teicoplanin loading doses ranging from 6-30 mg/kg, administered either 12-h for 154 three doses with one further dose 24 h later, or 12-h for five doses, to a standard 70 kg patient with 155 a CL CR of 70 mL/min were simulated. Seven levels of renal function (CL CR 20, 40, 70, 90, 120, 140 and 156 170 mL/min), which reflected the distribution of values observed in the study cohort, were also 157 tested. The PTAs for achieving a target trough concentration at 72 h (trough 72h ) of ≥20 mg/L, and an 158 AUC 48-72h /MIC of ≥800, were calculated. These targets were based on those suggested from 159 previously published studies. 8, 13, 16 IV teicoplanin maintenance doses ranging from 2-30 mg/kg once 160 daily to a 70 kg patient with various CL CR values (CL CR 20, 40, 70, 90, 120, 140 and 170 mL/min) were 161 also simulated. The PTA for achieving a target trough concentration on Day 7 of ≥20 mg/L was 162 calculated. The PTA (risk) of achieving a trough concentration on Day 7 of ≥60 mg/L, the suggested 163 upper limit for teicoplanin trough concentrations, 22 was also calculated. 164
Statistical analyses 165
All statistical analyses were conducted using IBM SPSS Statistics for Windows v. 22 (IBM Corp., Armonk, 166 NY) or Minitab 16 Statistical Software (Minitab Ltd., Coventry, UK). Data were described as the mean ± 167 SD or the median (IQR) for continuous variables, and as the number (%) for categorical variables, as 168 appropriate. Correlation between continuous variables was evaluated using the Pearson correlation 169 coefficient (r). Statistical significance was defined as P<0.05. 170
171
Results
172
Thirty patients with suspected or confirmed Gram-positive infection were recruited into the study 173 per protocol. Overall, the cohort was of older age, with mild renal impairment, low serum albumin 174 concentrations and severe neutropaenia. A summary of demographic and clinical characteristics of 175 included patients is provided in Table 1 . A CL CR of 1 mL/min was assumed for one patient based on 176 the urine output of ~10 mL on Day 3. 177
Serum teicoplanin concentrations 178
In total, 352 serum teicoplanin concentrations were analysed. The median (IQR) trough 179 concentrations at 48 h and 72 h were 15.9 (7.6) mg/L and 18.5 (7.9) mg/L, respectively. The median 180 (IQR) teicoplanin AUC 48-72h 
Teicoplanin MICs 185
Antibiotic susceptibility testing was conducted on 28 CoNS isolates from blood cultures taken from 186 study patients. Of these, 25 were meticillin-resistant (89.3%). Teicoplanin MICs for CoNS isolates 187 ranged from highly susceptible to fully resistant (0.125-8 mg/L), with a median (IQR) of 188
Pharmacokinetic model building
190
The teicoplanin concentration-time data were best described by a three-compartment linear model, 191 which was associated with a significant reduction in the log-likelihood value compared to the two-192 compartment model (LLD=232,  regimens (loading and maintenance doses) associated with a probability of ≥90% for achieving a 217 target trough concentration of ≥20 mg/L at 72 h and on Day 7, together with the probability (risk) of 218 achieving a trough concentration of ≥60 mg/L on Day 7, is provided in Table 3 . 219 220
Discussion
221
The results of this study suggest that standard teicoplanin dosing regimens are not suitable for 222 patients with haematological malignancy. An individualised dosing approach may be particularly 223 appropriate for these patients due to the high PK variability observed between patients. Using 224
Monte Carlo simulations, dosing regimens associated with a high likelihood of attaining target 225 teicoplanin concentrations were determined. These simulations suggested that stratifying doses 226 according to body weight and renal function may minimise the number of patients with suboptimal 227 teicoplanin exposures. 228
Many studies have questioned whether standard doses of teicoplanin, such as those specified in the 229 SmPC, can reliably produce timely therapeutic trough concentrations in clinical practice and there is 230 now an abundance of evidence, particularly for deep-seated staphylococcal infections, suggesting 231 the need for higher doses . 6, [22] [23] [24] The need for higher doses and higher target trough concentrations 232 is now recognised for bone and joint infections and infective endocarditis, with the SmPC 233 recommending 3-5 loading doses of 12 mg/kg 12-h followed by 12 mg/kg once daily. 15 Two 234 prominent PK studies of teicoplanin in haematological malignancy patients, of a similar size to the 235 current study, have been published previously and these studies suggested a need for high loading 236 doses of teicoplanin in these patients. 8, 25 However, these studies fitted comparatively sparse 237 sampling data to a two-compartment PK model. Most early studies of teicoplanin PK in healthy 238 volunteers, based on extensive sampling data, described teicoplanin PK as tri-exponential. 26, 27 Using 239 a two-compartment model for teicoplanin may not fully characterise the very slow distribution of 240 teicoplanin into some tissues and therefore not capture the gradual accumulation of teicoplanin in 241 the body over time. Furthermore, these previous studies of teicoplanin in haematological 242 malignancy patients did not attempt to stratify dosing according to renal function. This might be 243 particularly important for teicoplanin given that it is known to be virtually completely cleared 244 renally. The dosing simulations provided in Figure 2 suggest that administration of an extra loading dose at 254 36 h increases the likelihood of achieving optimal exposure within 72 h. For a typical haematological 255 malignancy patient, with a TBW of 70 kg and CL CR of 70 mL/min, the simulations suggest a loading 256 regimen of 12 mg/kg 12-h for five doses would be needed to ensure a high likelihood of achieving a 257 target trough concentration of ≥20 mg/L at 72 h. For a 90% PTA of achieving an AUC/MIC target of 258 800, a loading regimen of 15 mg/kg 12-h for five doses would be adequate for a pathogen with an 259 MIC of 1 mg/L. However, for pathogens with MICs >1 mg/L, which occurred in 57% of CoNS isolates 260 in this cohort, very high loading doses of teicoplanin would be needed to achieve the same level of 261 level of exposure. In these cases, it may be prudent to consider using an alternative antibiotic. 262
It must also be recognised that repeated exposure to suboptimal concentrations is an important risk 263 factor for the development of teicoplanin resistance.
6 Breakthrough resistance to teicoplanin during 264 treatment for CoNS infection has been documented and resulted in treatment failure. 29 Underdosing 265 should therefore be avoided, but by how much teicoplanin doses need to be increased to suppress 266 emergence of resistance, without compromising safety, has not been determined. The proposed 267 dosing regimens stratified by CL CR provided in Table 3 were associated with a high likelihood of 268 achieving and maintaining target trough concentrations as well as a relatively low risk of attaining 269 trough concentrations ≥60 mg/L on Day 7; the suggested upper limit for teicoplanin trough 270 concentrations. 22 Further studies are required to establish the teicoplanin exposure necessary to 271 achieve clinical efficacy while simultaneously suppressing emergence of resistance. It has been 272 previously suggested that maintenance doses be administered 12-h to ensure maintenance of 273 trough concentrations close to 20 mg/L. 8 However, a trough concentration of 20 mg/L taken 12 h 274 post-dose is not equivalent to a trough concentration of 20 mg/L taken 24 h post dose in terms of 275 total exposure. Larger total daily doses will, in addition to maintaining target trough concentrations, 276 provide greater total exposure and, as AUC/MIC is considered to be the PK/PD index best associated 277 with glycopeptide efficacy, may be preferable from an efficacy perspective.
11 Indeed, a recently 278 published nonclinical study of vancomycin PD for CoNS infection suggested that AUC/MIC and 279 peak/MIC were the dominant PD indices and that less-fractionated dosing regimens may be 280 associated with increased efficacy and reduced risk of emergence of antimicrobial resistance.
281
An important finding of this study was the very strong correlation observed between teicoplanin 282 trough 72h and AUC 48-72h , which supports the use of teicoplanin trough concentrations as a surrogate 283 marker of AUC for therapeutic drug monitoring purposes. Similar findings were reported in a 284 recently published study of teicoplanin in children with haematological malignancy.
5 Furthermore, 285
the results of the current study indicated that a trough 72h of 20 mg/L correlated with an AUC 48-72h of 286 ~800 mg.h/L; a target previously associated with efficacy.
287
The strengths of this study were the high quality, rich sampling data obtained prospectively under 288 clinical trial conditions, following administration of higher than standard teicoplanin doses, to inform 289 our population PK model and dosing simulations. We also used local teicoplanin MIC data from 290
Gram-positive blood isolates taken from study patients to assess PK/PD target attainment. However, 291
we acknowledge that the sample size was small and the data were obtained from a single institution 292 and therefore may not be representative of patients admitted to other institutions. Another notable 293 limitation is that the PK/PD targets for teicoplanin are not well defined and therefore the dosing 294 recommendations based on the assumed targets of the current study may be different should new 295 targets be established in the future. However, our dosing simulations provide PTAs for dosing 296 regimens covering a range of trough concentration targets. Further studies are needed to clarify the 297 PK/PD target for teicoplanin in neutropaenic patients and to confirm any advantage of higher doses 298 on clinical efficacy together with any increased risk of toxicity. Finally, this study did not address 299 unbound teicoplanin concentrations. As teicoplanin is highly protein bound and as patients with 300 haematological malignancy often have low serum albumin concentrations, altered protein binding 301 might be expected. Further work focussing on unbound teicoplanin PK would be valuable. 302
Nevertheless, as only total teicoplanin concentrations are monitored in practice, the results of this 303 study are clinically relevant. 304
In conclusion, this study has shown that when haematological malignancy patients are treated with 305 standard teicoplanin dosages many may fail to reach therapeutic targets that may be predictive of 306 clinical success. Increasing both the magnitude and number of loading doses administered increases 307 the likelihood of achieving therapeutic targets early in therapy. Individualised loading and 308 maintenance dosing, according to body weight and renal function, is strongly recommended to 309 ; V c , typical estimate of volume of the central compartment for a total body weight of 70 kg; K cp , first-order rate constant for drug distribution from the central to peripheral compartment; K pc , first-order rate constant for drug distribution from the peripheral to central compartment; K cdp , first-order rate constant for drug distribution from the central to deep peripheral compartment; K dpc , first-order rate constant for drug distribution from the deep peripheral to central compartment. 407 Table 3 . Teicoplanin dosage regimens associated with a probability of ≥90% for achieving trough concentrations of ≥20 mg/L at 72 h and on Day 7, and the probability (risk) of attaining trough concentrations ≥60 mg/L on Day 7, for a patient with a total body weight of 70 kg and various CL CR values CL CR (mL/min)
